Mirum Pharmaceuticals Inc. Insider Trading

MIRM

Last 12 months

Insiders bought $9M and sold $44M on the open market.

63% of the selling was scheduled in advance under 10b5-1 plans. SVP, Global Controller Jolanda Howe sold $4M on Aug 18, 97% of their stake, outside a plan.

Net open-market

−$35M

1 buy · 43 sales

Under a 10b5-1 plan

63%

of the value sold

Insiders who bought / sold

1 / 7

executives and directors

Last open-market buy

Jan 2026

Jan 23, 2026

Get an email when MIRM's executives or directors buy, or make a large sale outside a plan.

Trades · last 2 years

Date	Insider	Trade	Shares	Price	Value	Of their stake	Filing
Nov 4	Christopher Peetz Chief Executive Officer	Sold10b5-1 plan	20,000	$90.00	$1.8M	4.8%	Form 4
Sep 14	Eric Bjerkholt Chief Financial Officer	SoldNo plan	9,943	$98.37	978K	18%	Form 4
Sep 2	Jolanda Howe SVP, Global Controller	Sold10b5-1 plan	658	$100.00	66K	52%	Form 4
Sep 1	Christopher Peetz Chief Executive Officer	Sold10b5-1 plan 2 parts	30,000	$98.68 average	$2.96M	7.3%	Form 4
Aug 18	Jolanda Howe SVP, Global Controller	SoldNo plan	40,000	$100.00	$4M	97%	Form 4
Aug 11	Eric Bjerkholt Chief Financial Officer	Sold10b5-1 plan	6,001	$99.90	599K	14%	Form 4
Aug 10	Christopher Peetz Chief Executive Officer	Sold10b5-1 plan 3 parts	20,000	$98.92 average	$1.98M	5.0%	Form 4
Aug 3	Jolanda Howe SVP, Global Controller	Sold10b5-1 plan	1,840	$105.29	194K	59%	Form 4
Jul 6	Christopher Peetz Chief Executive Officer	Sold10b5-1 plan 4 parts	20,000	$122.27 average	$2.45M	5.0%	Form 4
Jul 6	Eric Bjerkholt Chief Financial Officer	Sold10b5-1 plan 4 parts	5,000	$122.25 average	611K	11%	Form 4
Jul 1	Jolanda Howe SVP, Global Controller	Sold10b5-1 plan	2,721	$120.00	327K	47%	Form 4
Jun 17	Jolanda Howe SVP, Global Controller	Sold10b5-1 plan	2,594	$101.95	264K	31%	Form 4
Jun 8	Eric Bjerkholt Chief Financial Officer	Sold10b5-1 plan 3 parts	5,000	$93.82 average	469K	9.6%	Form 4
Jun 1	Christopher Peetz Chief Executive Officer	Sold10b5-1 plan 6 parts	30,000	$95.84 average	$2.88M	7.3%	Form 4
Jun 1	Saira Ramasastry Director	Sold10b5-1 plan	3,977	$100.00	398K	100%	Form 4
May 15	Saira Ramasastry Director	Sold10b5-1 plan	2,000	$109.47	219K	100%	Form 4
Apr 15	Saira Ramasastry Director	Sold10b5-1 plan	2,000	$96.90	194K	100%	Form 4
Mar 16	Jolanda Howe SVP, Global Controller	SoldNo plan	4,732	$91.98	435K	36%	Form 4
Mar 16	Joanne Quan Chief Medical Officer	SoldNo plan	7,287	$91.98	670K	28%	Form 4
Mar 16	Peter Radovich President and COO	SoldNo plan	16,515	$91.98	$1.52M	29%	Form 4
Mar 16	Christopher Peetz Chief Executive Officer	SoldNo plan	40,985	$91.98	$3.77M	9.7%	Form 4
Mar 16	Saira Ramasastry Director	Sold10b5-1 plan	2,000	$90.76	182K	100%	Form 4
Mar 16	Eric Bjerkholt Chief Financial Officer	SoldNo plan	7,287	$91.98	670K	13%	Form 4
Feb 13	Saira Ramasastry Director	Sold10b5-1 plan	2,000	$102.09	204K	100%	Form 4
Feb 2	Jolanda Howe SVP, Global Controller	SoldNo plan	968	$103.30	100K	18%	Form 4
Feb 2	Peter Radovich President and COO	SoldNo plan	2,631	$103.30	272K	11%	Form 4
Feb 2	Christopher Peetz Chief Executive Officer	SoldNo plan	9,108	$103.30	941K	2.6%	Form 4
Jan 26	Jolanda Howe SVP, Global Controller	SoldNo plan	842	$96.19	81K	19%	Form 4
Jan 26	Peter Radovich President and COO	SoldNo plan	3,143	$96.19	302K	12%	Form 4
Jan 26	Christopher Peetz Chief Executive Officer	SoldNo plan	6,831	$96.19	657K	1.9%	Form 4
Jan 26	Eric Bjerkholt Chief Financial Officer	SoldNo plan	1,053	$96.19	101K	2.4%	Form 4
Jan 23	Patrick J Heron Director	Bought	131,425	$68.48	$9M	3.4%	Form 4
Jan 22	Jolanda Howe SVP, Global Controller	SoldNo plan	926	$93.33	86K	23%	Form 4
Jan 22	Joanne Quan Chief Medical Officer	SoldNo plan	1,822	$93.33	170K	12%	Form 4
Jan 22	Peter Radovich President and COO	SoldNo plan	2,382	$93.33	222K	10%	Form 4
Jan 22	Christopher Peetz Chief Executive Officer	SoldNo plan	7,098	$93.33	662K	2.0%	Form 4
Jan 22	Eric Bjerkholt Chief Financial Officer	SoldNo plan	1,421	$93.33	133K	3.3%	Form 4
Jan 20	Joanne Quan Chief Medical Officer	SoldNo plan	6,911	$90.27	624K	38%	Form 4
Jan 15	Saira Ramasastry Director	Sold10b5-1 plan	2,000	$90.99	182K	100%	Form 4
Dec 22, 2025	Saira Ramasastry Director	Sold10b5-1 plan	5,000	$80.00	400K	100%	Form 4

Nov 410b5-1 plan
Christopher Peetz
Chief Executive Officer · sold 20,000 at $90.00
$1.8M
4.8% of stake
Sep 14No plan
Eric Bjerkholt
Chief Financial Officer · sold 9,943 at $98.37
978K
18% of stake
Sep 210b5-1 plan
Jolanda Howe
SVP, Global Controller · sold 658 at $100.00
66K
52% of stake
Sep 110b5-1 plan
Christopher Peetz
Chief Executive Officer · sold 30,000 at avg $98.68
$2.96M
7.3% of stake
Aug 18No plan
Jolanda Howe
SVP, Global Controller · sold 40,000 at $100.00
$4M
97% of stake
Aug 1110b5-1 plan
Eric Bjerkholt
Chief Financial Officer · sold 6,001 at $99.90
599K
14% of stake
Aug 1010b5-1 plan
Christopher Peetz
Chief Executive Officer · sold 20,000 at avg $98.92
$1.98M
5.0% of stake
Aug 310b5-1 plan
Jolanda Howe
SVP, Global Controller · sold 1,840 at $105.29
194K
59% of stake
Jul 610b5-1 plan
Christopher Peetz
Chief Executive Officer · sold 20,000 at avg $122.27
$2.45M
5.0% of stake
Jul 610b5-1 plan
Eric Bjerkholt
Chief Financial Officer · sold 5,000 at avg $122.25
611K
11% of stake
Jul 110b5-1 plan
Jolanda Howe
SVP, Global Controller · sold 2,721 at $120.00
327K
47% of stake
Jun 1710b5-1 plan
Jolanda Howe
SVP, Global Controller · sold 2,594 at $101.95
264K
31% of stake
Jun 810b5-1 plan
Eric Bjerkholt
Chief Financial Officer · sold 5,000 at avg $93.82
469K
9.6% of stake
Jun 110b5-1 plan
Christopher Peetz
Chief Executive Officer · sold 30,000 at avg $95.84
$2.88M
7.3% of stake
Jun 110b5-1 plan
Saira Ramasastry
Director · sold 3,977 at $100.00
398K
100% of stake
May 1510b5-1 plan
Saira Ramasastry
Director · sold 2,000 at $109.47
219K
100% of stake
Apr 1510b5-1 plan
Saira Ramasastry
Director · sold 2,000 at $96.90
194K
100% of stake
Mar 16No plan
Jolanda Howe
SVP, Global Controller · sold 4,732 at $91.98
435K
36% of stake
Mar 16No plan
Joanne Quan
Chief Medical Officer · sold 7,287 at $91.98
670K
28% of stake
Mar 16No plan
Peter Radovich
President and COO · sold 16,515 at $91.98
$1.52M
29% of stake
Mar 16No plan
Christopher Peetz
Chief Executive Officer · sold 40,985 at $91.98
$3.77M
9.7% of stake
Mar 1610b5-1 plan
Saira Ramasastry
Director · sold 2,000 at $90.76
182K
100% of stake
Mar 16No plan
Eric Bjerkholt
Chief Financial Officer · sold 7,287 at $91.98
670K
13% of stake
Feb 1310b5-1 plan
Saira Ramasastry
Director · sold 2,000 at $102.09
204K
100% of stake
Feb 2No plan
Jolanda Howe
SVP, Global Controller · sold 968 at $103.30
100K
18% of stake
Feb 2No plan
Peter Radovich
President and COO · sold 2,631 at $103.30
272K
11% of stake
Feb 2No plan
Christopher Peetz
Chief Executive Officer · sold 9,108 at $103.30
941K
2.6% of stake
Jan 26No plan
Jolanda Howe
SVP, Global Controller · sold 842 at $96.19
81K
19% of stake
Jan 26No plan
Peter Radovich
President and COO · sold 3,143 at $96.19
302K
12% of stake
Jan 26No plan
Christopher Peetz
Chief Executive Officer · sold 6,831 at $96.19
657K
1.9% of stake
Jan 26No plan
Eric Bjerkholt
Chief Financial Officer · sold 1,053 at $96.19
101K
2.4% of stake
Jan 23
Patrick J Heron
Director · bought 131,425 at $68.48
$9M
3.4% of stake
Jan 22No plan
Jolanda Howe
SVP, Global Controller · sold 926 at $93.33
86K
23% of stake
Jan 22No plan
Joanne Quan
Chief Medical Officer · sold 1,822 at $93.33
170K
12% of stake
Jan 22No plan
Peter Radovich
President and COO · sold 2,382 at $93.33
222K
10% of stake
Jan 22No plan
Christopher Peetz
Chief Executive Officer · sold 7,098 at $93.33
662K
2.0% of stake
Jan 22No plan
Eric Bjerkholt
Chief Financial Officer · sold 1,421 at $93.33
133K
3.3% of stake
Jan 20No plan
Joanne Quan
Chief Medical Officer · sold 6,911 at $90.27
624K
38% of stake
Jan 1510b5-1 plan
Saira Ramasastry
Director · sold 2,000 at $90.99
182K
100% of stake
Dec 22, 202510b5-1 plan
Saira Ramasastry
Director · sold 5,000 at $80.00
400K
100% of stake

How to read this. Insiders sell for many reasons: taxes, diversifying, a house. Open-market buys are rarer and say more. A 10b5-1 plan is a trading schedule set up months in advance, so those sales were not timed on news. Large holders (funds and 10% owners) are listed under Everything but not counted as insiders. If you own or watch MIRM, we send a push when an executive buys or makes a large sale outside a plan.

Source: SEC Form 4 filings, filed within two business days of each trade and checked for new ones every hour.

Peers

Pharmaceutical Preparations · Pick stocks to compare with MIRM

CompareIntrinsic value

ARWRArrowhead Pharmaceuticals Inc.

$61.65+3.56%40

TVTXTravere Therapeutics Inc.

$52.64+6.54%52

NRIXNurix Therapeutics Inc.

$15.95-38.23%84

FOLDAmicus Therapeutics, Inc.

No recent price45

RAREUltragenyx Pharmaceutical Inc.

$17.16+3.19%40

AMPHAmphastar Pharmaceuticals Inc.

$28.02+3.32%60

CPRXCatalyst Pharmaceuticals Inc.

No recent price73

PCRXPacira BioSciences Inc.

$36.40+0.03%58

Held by ETFs

MIRM is in 72 US ETFs. The largest of them, with MIRM's weight in each:

Spot a number that looks wrong? Check it in MIRM's SEC filings or

Download this analysis as a PDF (Pro)

Data sourced from SEC EDGAR filings and third-party price providers. Scores, valuations, and metrics are algorithmic estimates. This is not investment advice. See our Terms and Methodology.

2 of 2 free stocks used today

Keep analysing MIRM

Create a free account and get 14 days of Premium: every stock and every tool.

Unlimited stocksQuality, fair value and dividends for 10,000+ stocks
Stock screenerFilter on quality, valuation and dividend safety
Portfolio trackerReal return, dividend calendar and portfolio quality
Editable DCFChange the assumptions and watch fair value move
Compare side by sideUp to 10 stocks in one table
Unlimited alertsPrice, P/E, Quality Score and yield

No card. Moves to Free after, unless you upgrade.

Already have an account?

Or come back tomorrow. Stocks on your watchlist are always free to view.